FINVASIA-GROUP
18.4.2022 10:32:08 CEST | Business Wire | Press release
Finvasia today announced that it has appointed Tajinder Virk as the interim Chief Executive Officer for ZuluTrade. He will replace the previous CEO from the company, effective immediately.
"Tajinder has been instrumental in building upon Finvaisa’s success and has an impressive track record in delivering growth for our group companies," said Sarvjeet Singh Virk, CMD & Co-founder Finvasia. "We have seen Tajinder (A.K.A. Natty) in action first hand and have the utmost confidence that his deep financial experience and leadership skills will drive results and accelerate ZuluTrade’s business in this interim role."
Tajinder Virk is the CEO of Finvasia Group of companies and is an exceptional leader with deep familiarity with all aspects of the business that allows him to develop and lead the execution of the group’s strategic vision, assess risks and guide the group’s growth. He has worked with some of the largest investment banks and hedge funds on Wall Street and has managed multibillion-dollar funds for major US banks, before co-founding Finvasia. At ZuluTrade, Tajinder will work closely with the team to deliver on the business expansion plan.
Commenting on the appointment, Tajinder said, “Finvasia is known for its innovative business approach and for its ability to create value for its clients. We see ZuluTrade as the largest Social Wealth Management platform that will bring more asset classes and industry participants together under a single platform.
“ZuluTrade is among the largest and the original social trading platforms that revolutionised copy trading in 2008. ZuluTrade 2.0 will maintain its legacy of being broker neutral, so it has no conflict of interest with its investors. We will be offering a variety of asset classes, encouraging more investors, leaders and brokers to join the platform whilst creating a conducive environment for them to grow their wealth,” he continued.
Finvasia’s board has simultaneously commenced a formal search for a permanent CEO for ZuluTrade who can deliver on the Group’s expectations for future ready products while maintaining its core values and cultures.
About ZULUTRADE (https://www.zulutrade.com )
ZuluTrade is the original social trading platform that revolutionised copy trading in 2008. It offers a massive database of Algo signals and strategies currently available across the market, catering to both advanced and novice investors alike.
It's a broker neutral platform that has catered to over 2.5 million clients in over 100 countries and supports over twenty-six languages.
About FINVASIA (https://finvasia.com )
Finvasia is a multi-disciplinary, multinational organisation that owns and operates over a dozen brands across financial services, technology, real estate and healthcare verticals.
Finvasia Group has managed funds for some of the notable hedge funds of Wall street, launched the first and only commission free ecosystem for financial products in India and is now aggressively expanding its presence in the European market. The Group has provided technology to some of the notable listed and unlisted financial services entities across the globe.
Furthermore, its healthcare division recently launched a medically proven diabetes reversal program in India and has engaged scientists from various specialised fields in an effort to build nano and micro medical devices that will cater to the future of medical engineering.
In the last 13 years, Finvasia has catered to a few million clients in over 180 countries directly or via its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005251/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom